PT1015585E - Homologos de ligandos de tie - Google Patents

Homologos de ligandos de tie

Info

Publication number
PT1015585E
PT1015585E PT98946987T PT98946987T PT1015585E PT 1015585 E PT1015585 E PT 1015585E PT 98946987 T PT98946987 T PT 98946987T PT 98946987 T PT98946987 T PT 98946987T PT 1015585 E PT1015585 E PT 1015585E
Authority
PT
Portugal
Prior art keywords
tie
ligandos
homes
nucleic acid
acid molecules
Prior art date
Application number
PT98946987T
Other languages
English (en)
Inventor
Paul J Godowski
Austin L Gurney
Hillan Kenneth
Botstein David
Audrey Goddard
Roy Margaret
Ferrara Napoleone
Tumas Daniel
Schwall Ralph
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/933,821 external-priority patent/US5972338A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PT1015585E publication Critical patent/PT1015585E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT98946987T 1997-09-19 1998-09-14 Homologos de ligandos de tie PT1015585E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/933,821 US5972338A (en) 1997-09-19 1997-09-19 Tie ligands homologues
US08/960,507 US6057435A (en) 1997-09-19 1997-10-29 Tie ligand homologues

Publications (1)

Publication Number Publication Date
PT1015585E true PT1015585E (pt) 2006-10-31

Family

ID=27130048

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98946987T PT1015585E (pt) 1997-09-19 1998-09-14 Homologos de ligandos de tie

Country Status (15)

Country Link
US (3) US6057435A (pt)
EP (4) EP1724349A1 (pt)
JP (4) JP2001517437A (pt)
KR (4) KR100692333B1 (pt)
AT (1) ATE327329T1 (pt)
AU (1) AU756449B2 (pt)
CA (1) CA2304129A1 (pt)
CY (1) CY1105161T1 (pt)
DE (1) DE69834649T2 (pt)
DK (1) DK1015585T3 (pt)
ES (1) ES2268790T3 (pt)
IL (2) IL134648A0 (pt)
NZ (1) NZ502946A (pt)
PT (1) PT1015585E (pt)
WO (1) WO1999015653A2 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005972A1 (en) * 1999-07-20 2001-01-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6350450B1 (en) * 1997-09-19 2002-02-26 Genentech, Inc. TIE ligand homologue antibody
US6057435A (en) 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
WO1999032639A1 (en) * 1997-12-19 1999-07-01 Regeneron Pharmaceuticals, Inc. Receptor tyrosine kinase, ar-1, is a regulator of angiogenesis
AU2493699A (en) * 1998-02-04 1999-08-23 Zymogenetics Inc. Angiopoietin homolog zapo3, dna encoding it, and method of making it
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
WO1999062925A1 (en) * 1998-06-02 1999-12-09 Eli Lilly And Company Angiopoietin related gene sequence scarface 1
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1098665B9 (en) 1998-07-13 2003-08-13 The Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
IL140701A0 (en) * 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using antibodies to aminophospholipids
EP1098974A2 (en) * 1998-07-20 2001-05-16 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
AU5210899A (en) * 1998-07-24 2000-02-14 Eli Lilly And Company Angiopoietin related gene sequence scarface 2
AU5472899A (en) * 1998-08-20 2000-03-14 Incyte Pharmaceuticals, Inc. Human angiopoietin-3
US6537554B1 (en) 1998-09-10 2003-03-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US20050148101A1 (en) * 1999-01-23 2005-07-07 Bamdad Cynthia C. Interaction of colloid-immobilized species with species on non-colloidal structures
WO2000052167A1 (en) * 1999-03-02 2000-09-08 Regeneron Pharmaceuticals, Inc. Angiopoietin-related protein and nucleic acids
KR20010104373A (ko) * 1999-03-08 2001-11-24 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
ES2223705T3 (es) 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP1208195A2 (en) * 1999-06-15 2002-05-29 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6835381B1 (en) 1999-07-02 2004-12-28 Bayer Ag Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor
CA2377788A1 (en) * 1999-07-02 2001-01-11 Bayer Ag Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor
WO2001003735A1 (en) * 1999-07-12 2001-01-18 Maine Medical Center Research Institute Cancer treatment using angiopoietins targeted to aminophospholipids
AU1310201A (en) * 1999-10-21 2001-04-30 Royal Netherlands Academy Of Arts And Sciences Cdt6 can inhibit angiogenesis and tumor growth, and can induce or enhance the formation of structures containing collagen
CA2390438A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 19 human secreted proteins
AU2002216614A1 (en) * 2000-10-03 2002-04-15 Minerva Biotechnologies Corporation Electronic detection of interaction based on the interruption of flow
AU2002365261A1 (en) * 2001-10-18 2003-09-02 The Children's Hospital Of Philadelphia Methods and materials for the recruitment of endothelial cells
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003220805A1 (en) * 2002-03-28 2003-10-13 Yamanouchi Pharmaceutical Co., Ltd. Antiopoietin-related growth factor
CA2518627A1 (en) * 2003-06-06 2004-12-16 Astellas Pharma Inc. Method of screening antiobesity agents and animal model of obesity
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
JP2007528720A (ja) * 2003-08-12 2007-10-18 ダイアックス コーポレイション Ｔｉｅ１結合リガンド
EP1781824A2 (en) * 2004-08-25 2007-05-09 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CA2589538A1 (en) * 2004-12-03 2006-06-08 Astellas Pharma Inc. Method of screening antiobesity agents
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
WO2008089070A2 (en) * 2007-01-12 2008-07-24 Dyax Corp. Combination therapy for the treatment of cancer
US20090104210A1 (en) * 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US8921058B2 (en) 2009-10-26 2014-12-30 Externautics Spa Prostate tumor markers and methods of use thereof
US20130022983A1 (en) * 2009-10-26 2013-01-24 Externautics S.P.A. Colon and Rectal Tumor Markers and Methods of Use Thereof
EP2494361B2 (en) 2009-10-26 2019-01-09 Externautics S.p.A. Ovary tumor markers and methods of use thereof
KR101109486B1 (ko) * 2009-10-29 2012-01-31 현대제철 주식회사 크레인 그래브용 체결장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3353293A (en) * 1992-01-09 1993-08-03 Helsinki University Holding, Ltd. Tie, a novel endothelial cell receptor tyrosine kinase
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
AU4651893A (en) * 1992-06-26 1994-01-24 Immunex Corporation Novel tyrosine kinase
WO1995013387A1 (en) * 1993-11-12 1995-05-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tie-2, a novel receptor tyrosine kinase
US5643755A (en) * 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
AUPM379494A0 (en) * 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
AU701568B2 (en) * 1994-09-22 1999-02-04 Licentia Ltd Promoter for the receptor tyrosine kinase, tie
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) * 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
JP3434830B2 (ja) * 1994-10-13 2003-08-11 ザ・ボーイング・カンパニー ジェットエンジンのための騒音低減システムおよび騒音制御方法
EP0821728B1 (en) * 1995-04-06 2004-08-11 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
US5851797A (en) * 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
AU724467B2 (en) * 1996-06-19 2000-09-21 Regeneron Pharmaceuticals, Inc. TIE-2 receptor ligand (TIE ligand-4) and its uses
US6057435A (en) 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues

Also Published As

Publication number Publication date
DE69834649D1 (de) 2006-06-29
EP1696029A1 (en) 2006-08-30
JP2004129656A (ja) 2004-04-30
KR20060060061A (ko) 2006-06-02
JP2001517437A (ja) 2001-10-09
KR20060060060A (ko) 2006-06-02
JP2004097224A (ja) 2004-04-02
EP1015585B1 (en) 2006-05-24
ATE327329T1 (de) 2006-06-15
KR100692333B1 (ko) 2007-03-14
CY1105161T1 (el) 2009-11-04
CA2304129A1 (en) 1999-04-01
ES2268790T3 (es) 2007-03-16
JP2004113239A (ja) 2004-04-15
KR100692334B1 (ko) 2007-03-14
KR20060060062A (ko) 2006-06-02
WO1999015653A2 (en) 1999-04-01
DK1015585T3 (da) 2006-10-02
AU756449B2 (en) 2003-01-16
KR100692335B1 (ko) 2007-03-13
AU9388098A (en) 1999-04-12
IL134648A (en) 2007-08-19
US6551822B1 (en) 2003-04-22
WO1999015653A3 (en) 1999-05-20
EP1015585A2 (en) 2000-07-05
EP1724349A1 (en) 2006-11-22
KR100692336B1 (ko) 2007-03-14
US6057435A (en) 2000-05-02
IL134648A0 (en) 2001-04-30
NZ502946A (en) 2001-11-30
KR20010024146A (ko) 2001-03-26
US6413770B1 (en) 2002-07-02
EP1696030A1 (en) 2006-08-30
DE69834649T2 (de) 2007-05-03

Similar Documents

Publication Publication Date Title
PT1015585E (pt) Homologos de ligandos de tie
DK1482040T3 (da) NL3-TIE-receptortyrosinkinaseligandhomologer
SI1095140T1 (sl) Nevrotrofični dejavniki
PT765394E (pt) Lacases myceliophthora purificadas e acidos nucleicos que as codificam
DE69528061D1 (de) Gereinigte polyporus laccasen und dafür kodierende nukleinsäuren
WO2001075067A3 (en) Novel nucleic acids and polypeptides
DE69839444D1 (de) Smad 6 und dessen anwendungen
DE69518751D1 (de) Gereinigte scytalidium lacassen und nukleinsäuren dafür kodierend
WO2001053312A8 (en) Novel nucleic acids and polypeptides
WO2000018914A3 (en) Novel dkr polypeptides
PT1930439E (pt) Factores neurotróficos
WO2002072786A3 (en) Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
IL154298A0 (en) Papap proteins, their preparation and use
PE20399A1 (es) Muteina ob
WO2002046410A3 (en) Prostate-specific polypeptide pamp and encoding nucleic acid molecules
ATE320496T1 (de) Testisspezifische, menschliche proteinase, svph1- 8
NO20011961D0 (no) PRV-1-genet og anvendelsen av dette